eligibility_summary
Inclusion: CAR-T infusion 3–5 days before echocardiography, completed standard pre-therapy cardiac assessment (echocardiogram and ECG) before conditioning/infusion, not opposed to participation, affiliated with social security or state medical aid (AME). Exclusion: opposition to or withdrawal of consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial type: Observational. Intervention: bedside transthoracic echocardiography (D3–D5 post–CAR‑T) plus routine biomarkers (BNP, troponin), ECG, and cytokine profiling to detect early cardiotoxicity. Drug/therapy context: CAR‑T cells (cellular immunotherapy, autologous gene‑modified T lymphocytes engineered with chimeric antigen receptors) that recognize tumor antigens independently of MHC, used for refractory hematologic malignancies. Mechanism focus: potent T‑cell activation with cytokine release (CRS) potentially affecting the heart. Cells/pathways targeted: CAR‑T effector T cells against tumor antigens, cytokine‑driven inflammatory pathways, cardiac function (LVEF).